Key result
Preliminary clinical and animal studies suggest that angiotensin converting enzyme (ACE) inhibitors may delay the progression of diabetic nephropathy and preserve renal function.
Why the study?
Do ACE inhibitors preserve renal function in hypertensive and diabetic patients with renal failure?
Do ACE inhibitors preserve renal function in hypertensive and diabetic patients with renal failure?
ACE inhibitors may offer specific renoprotective effects in patients with diabetes and hypertension by controlling glomerular capillary hypertension.
Answers are grounded in this paper and cite their sources.
May support ACE inhibitor consideration in diabetic nephropathy with hypertension; leaves open need for definitive RCTs before practice change.
Recent studies in animal models suggest that glomerular capillary hyperperfusion and hypertension, rather than ischemia, cause renal injury. Interventions that control glomerular capillary hypertension may protect against progressive injury, even in the presence of continued systemic hypertension. In the absence of systemic hypertension, diabetes mellitus is a prominent clinical example of glomerular hypertension. Animal studies have shown that glomerular hemodynamic abnormalities, especially elevations in glomerular pressure, play an important role in the pathogenesis of diabetic glomerulopathy. A number of clinical observations suggest that angiotensin converting enzyme (ACE) inhibitors may delay the progression of diabetic nephropathy by their effects on renal hemodynamics. In experimental animals, comparisons between calcium channel blockers and ACE inhibitors have shown the latter to be more effective in protecting the kidneys. Preliminary clinical studies indicate that ACE inhibitors may have advantages in preserving renal function in hypertensive and diabetic patients with renal failure.
No takes yet. Share an insight, caveat, or question.
Sharon Anderson (1990) conducted a review in Hypertension and diabetic nephropathy. Angiotensin converting enzyme (ACE) inhibitors vs. Calcium channel blockers was evaluated. Preliminary clinical and animal studies suggest that angiotensin converting enzyme (ACE) inhibitors may delay the progression of diabetic nephropathy and preserve renal function.
Synapse has enriched 10 related papers. Consider them for comparative context: